In one subject, IL-13Rα2-targeted CAR T treatment altered the tumor microenvironment (TME) by activating the host immune system to target the tumor through enhanced IFN-γ signaling after CAR treatment, which subsequently resulted in subsequential complete response in the subject [101]. This evidence concerns the gene IFNG and neoplasm.